LICENSE AGREEMENTLicense Agreement • August 14th, 2020 • Tarsus Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • New York
THIS LICENSE AGREEMENT (the “Agreement”), dated as of January 31, 2019 (the “Effective Date”), is made and entered into by and between Elanco Tiergesundheit AG, a Swiss corporation having place of business at Mattenstrasse 24A, 4058 Basel, Switzerland (“Elanco”) and Tarsus Pharmaceuticals, Inc., a Delaware corporation having its principal offices at 4590 MacArthur Blvd. Suite 500, Newport Beach, CA 92660 (“Tarsus”). Each of Elanco and Tarsus may be referred to herein as a “Party” and collectively as the “Parties.”
